371 related articles for article (PubMed ID: 18317450)
1. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
Billottet C; Banerjee L; Vanhaesebroeck B; Khwaja A
Cancer Res; 2009 Feb; 69(3):1027-36. PubMed ID: 19176369
[TBL] [Abstract][Full Text] [Related]
4. PTEN, more than the AKT pathway.
Blanco-Aparicio C; Renner O; Leal JF; Carnero A
Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
[TBL] [Abstract][Full Text] [Related]
5. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
Bibollet-Bahena O; Almazan G
J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
[TBL] [Abstract][Full Text] [Related]
6. The p85 regulatory subunit of PI3K mediates TSH-cAMP-PKA growth and survival signals.
De Gregorio G; Coppa A; Cosentino C; Ucci S; Messina S; Nicolussi A; D'Inzeo S; Di Pardo A; Avvedimento EV; Porcellini A
Oncogene; 2007 Mar; 26(14):2039-47. PubMed ID: 17043656
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
Ren SY; Xue F; Feng J; Skorski T
Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
[TBL] [Abstract][Full Text] [Related]
8. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
9. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.
Carson JD; Van Aller G; Lehr R; Sinnamon RH; Kirkpatrick RB; Auger KR; Dhanak D; Copeland RA; Gontarek RR; Tummino PJ; Luo L
Biochem J; 2008 Jan; 409(2):519-24. PubMed ID: 17877460
[TBL] [Abstract][Full Text] [Related]
10. Reelin signals through phosphatidylinositol 3-kinase and Akt to control cortical development and through mTor to regulate dendritic growth.
Jossin Y; Goffinet AM
Mol Cell Biol; 2007 Oct; 27(20):7113-24. PubMed ID: 17698586
[TBL] [Abstract][Full Text] [Related]
11. Zinc chloride stimulates DNA synthesis of mouse embryonic stem cells: involvement of PI3K/Akt, MAPKs, and mTOR.
Ryu JM; Lee MY; Yun SP; Han HJ
J Cell Physiol; 2009 Mar; 218(3):558-67. PubMed ID: 18988195
[TBL] [Abstract][Full Text] [Related]
12. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
Hofmann BT; Jücker M
Cell Signal; 2012 Oct; 24(10):1950-4. PubMed ID: 22735814
[TBL] [Abstract][Full Text] [Related]
13. KIT and mastocytosis.
Lim KH; Pardanani A; Tefferi A
Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
[TBL] [Abstract][Full Text] [Related]
14. The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase.
Martin MJ; Melnyk N; Pollard M; Bowden M; Leong H; Podor TJ; Gleave M; Sorensen PH
Mol Cell Biol; 2006 Mar; 26(5):1754-69. PubMed ID: 16478996
[TBL] [Abstract][Full Text] [Related]
15. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant.
Chian R; Young S; Danilkovitch-Miagkova A; Rönnstrand L; Leonard E; Ferrao P; Ashman L; Linnekin D
Blood; 2001 Sep; 98(5):1365-73. PubMed ID: 11520784
[TBL] [Abstract][Full Text] [Related]
16. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
17. Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor.
Young SM; Cambareri AC; Odell A; Geary SM; Ashman LK
Cell Signal; 2007 Dec; 19(12):2572-81. PubMed ID: 17855052
[TBL] [Abstract][Full Text] [Related]
18. Phosphoinositide 3-kinase: from viral oncoprotein to drug target.
Vogt PK; Bader AG; Kang S
Virology; 2006 Jan; 344(1):131-8. PubMed ID: 16364744
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
[TBL] [Abstract][Full Text] [Related]
20. Thyroid-hormone-dependent activation of the phosphoinositide 3-kinase/Akt cascade requires Src and enhances neuronal survival.
Cao X; Kambe F; Yamauchi M; Seo H
Biochem J; 2009 Nov; 424(2):201-9. PubMed ID: 19747164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
